

# Lydia Wai Ting Cheung

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7725437/lydia-wai-ting-cheung-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

1,603

citations

15

h-index

27

g-index

27

ext. papers

1,933

ext. citations

10.7

avg, IF

4.04

L-index

#	Paper	IF	Citations
26	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. <i>Cancer Discovery</i> , <b>2011</b> , 1, 170-85	24.4	342
25	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , <b>2015</b> , 28, 515-528	24.3	278
24	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. <i>Genome Research</i> , <b>2012</b> , 22, 2120-9	9.7	178
23	Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. <i>Molecular Endocrinology</i> , <b>2008</b> , 22, 2085-98		148
22	Systematic Functional Annotation of Somatic Mutations in Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 450-462.e10	24.3	114
21	Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. <i>FEBS Journal</i> , <b>2008</b> , 275, 5479-95	5.7	97
20	Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. <i>Cancer Research</i> , <b>2006</b> , 66, 10902-10	10.1	81
19	Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. <i>Endocrinology</i> , <b>2006</b> , 147, 4179-91	4.8	71
18	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. <i>Cancer Cell</i> , <b>2014</b> , 26, 479-94	24.3	61
17	Regulation of the PI3K pathway through a p85 monomer-homodimer equilibrium. <i>ELife</i> , <b>2015</b> , 4, e068668.9		46
16	Somatic mutations of PIK3R1 promote gliomagenesis. <i>PLoS ONE</i> , <b>2012</b> , 7, e49466	3.7	40
15	Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fibroblast growth factor receptor-1. <i>Cardiovascular Research</i> , <b>2011</b> , 89, 419-25	9.9	39
14	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 716	17.4	22
13	Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion. <i>Molecular Therapy</i> , <b>2013</b> , 21, 78-90	11.7	18
12	Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. <i>Endocrine</i> , <b>2007</b> , 31, 311-20		17
11	Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis. <i>Science of the Total Environment</i> , <b>2021</b> , 762, 143159	10.2	13
10	A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets. <i>Cell Reports</i> , <b>2020</b> , 32, 108020	10.6	10

9	p85 $\beta$ regulates autophagic degradation of AXL to activate oncogenic signaling. <i>Nature Communications</i> , <b>2020</b> , 11, 2291	17.4	6
8	CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes. <i>FEBS Letters</i> , <b>2007</b> , 581, 4668-74	3.8	6
7	A pathway map of AXL receptor-mediated signaling network. <i>Journal of Cell Communication and Signaling</i> , <b>2021</b> , 15, 143-148	5.2	5
6	Cancer-associated missense mutations enhance the pluripotency reprogramming activity of OCT4 and SOX17. <i>FEBS Journal</i> , <b>2020</b> , 287, 122-144	5.7	4
5	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 262	12.8	3
4	p85 $\beta$ alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair. <i>Neoplasia</i> , <b>2021</b> , 23, 718-730	6.4	2
3	Strategic Combination Therapies for Ovarian Cancer. <i>Current Cancer Drug Targets</i> , <b>2020</b> , 20, 573-585	2.8	1
2	Cancer-associated mutations in the p85 $\beta$ -terminal SH2 domain activate a spectrum of receptor tyrosine kinases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	1
1	Oncogenic pathway driven by p85 $\beta$ upstream signals to activate p110. <i>Molecular and Cellular Oncology</i> , <b>2020</b> , 7, 1780900	1.2	0